|
|
|
|
NARFE December 2025
With the holiday season upon us, we'd like to celebrate NARFE's incredible dedication and partnership. Your unwavering support fuels hope and help for the more than 7 million Americans living with Alzheimer's and the nearly 12 million caregivers who stand beside them. Thanks to the passion of NARFE Walk to End Alzheimer's® teams, an amazing $96,753 has already been raised this year to advance Alzheimer's care, support and research! The finish line is in sight, but there's still time to make an impact. Last-minute Walk donations can be turned in through Dec. 31, and with one final push, NARFE can reach its $100,000 goal. If you couldn't join a Walk team this year, you can still make a difference by giving directly to one of the NARFE teams. Every gift brings us closer to our vision of a world without Alzheimer's and all other dementia. Thank you for your extraordinary commitment to the Alzheimer's Association and the fight to end this relentless disease. Wishing you a joyful, healthy holiday season!
|
|
|
Our Helpline is here for you during the holidays
The Alzheimer's Association 24/7 Helpline (800.272.3900) provides free, year-round support for people living with dementia, caregivers, families and the public — even on holidays. Connect with a live person who can provide information, local resources, crisis assistance and emotional support. Learn more.
|
|
|
|
|
Holiday travel may overwhelm someone living with Alzheimer's
When visiting friends and family over the holidays, it's important to consider the difficulties and benefits of travel for someone living with Alzheimer's or another dementia. In the early stages, the person may still enjoy traveling, but it may become overwhelming as the disease progresses. Learn more.
|
|
|
|
|
U.S. POINTER add-on studies show multiple benefits
Three U.S. POINTER add-on studies reported positive results. The research showed that people following the U.S. POINTER "recipe" of healthy lifestyle intervention with regular structured support saw improved blood pressure regulation of blood flow to the brain; reduced sleep apnea respiratory events; and increased cognitive resilience for adults with certain Alzheimer's-related brain changes. Learn more.
|
|
|
|
|
New semaglutide studies disappointing; our work more important than ever
Results released last month from two major new studies testing an oral semaglutide pill for the treatment of early-stage symptomatic Alzheimer's did not demonstrate a statistically significant reduction in disease progression. The Alzheimer's Association is disappointed in the results, but this research will contribute to our understanding of this devastating and fatal disease. Learn more.
|
|
|
|
|
View Past Issues
|
|
|
|
|
NARFE 2026 Goal: $17 Million
|
|
|
|
24/7 Helpline: 1-800-272-3900
|
|
